Strategic acquisitions Ionpath’s 2025 acquisition of MIBIscope™ IP and ongoing support for MIBIscope™ systems indicate a focus on expanding spatial proteomics capabilities and customer maintenance revenues. Target customers using or evaluating MIBIscope and related imaging workflows may be ripe for upsell to advanced platforms or extended service agreements.

Product leadership Recent launch of mibiscope 3.0 positions Ionpath as a technology leader in high-definition spatial proteomics. Potential sales opportunities exist in upgrading existing customers to 3.0, as well as converting competitors’ users seeking improved imaging resolution and throughput.

Financing momentum Historic Series B funding with participation from Bruker and Samsara BioCapital signals strong investor support and scale potential. This can be leveraged to pursue multi-year procurement deals, bundled instruments, and expansion into hybrid workflows integrating mass spectrometry and spatial imaging.

Executive alignment New C-suite leadership and seasoned marketing personnel indicate a push to scale commercial efforts. Engage at strategic levels with Chief Commercial Officer and senior marketing leaders to shape enterprise sales motions, channel partnerships, and international expansion plans.

Market positioning Ionpath sits in a competitive landscape with mid-tier players and high-end incumbents. Emphasize value propositions around spatial proteomics capabilities, platform stability, and global support to win lab deployments, service contracts, and cross-sell opportunities to labs already invested in related technologies.